Research
Hormonal
In postmenopausal women with a normal baseline BMI (<25.0), gaining more than 5% of body weight during follow-up is associated with an increased risk of invasive breast cancer.
Postmenopausal women with a normal weight should be vigilant about avoiding significant weight gain (more than 5% of body weight), as this increases breast cancer risk. This highlights that weight stability is important even for those who are not currently overweight.
StrongQualifiesHIGH confidence
Women with a baseline BMI of less than 25.0 who gained more than 5% of body weight over the follow-up period had an increased breast cancer risk (HR, 1.36; 95% CI, 1.1-1.65)
Why this rating
Derived from the same large-scale WHI trial with rigorous measurement.
Source
Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk
Marian L. Neuhouser et al. · JAMA Oncology · 2015
DOI 10.1001/jamaoncol.2015.1546
rct · n=67142Cited 629×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →